Prolonged Response To Treatment With Ipilimumab In A Patient With A Diagnosis Of Disseminated Malignant Melanoma

Ipilimumab is a first immune checkpoints inhibitors. Ipilimumab is a standard therapy for advanced melanoma. In Poland the reimburoment of this drug includes only melanoma of the skin in the second line systemic therapy. We describe a case of a middle-age woman with a diagnosis of malignant disseminated melanoma (primary diagnosis was adenocarcinoma) in which the use of ipilimumab induction in second line treatment resulted long-term clinical benefit - 30 months free of the disease symptoms.